Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 5/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.39 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.39 |
| ▸ | MGLL | Q99685 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | GBA1 | P04062 | 1/20 | 0.34 |
| ▸ | GGPS1 | O95749 | 3/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20142321 | 1.00 | DNM1 (0.46) | DNM1TSHRTHRBPLA2G1BPLA2G2A | |
| SCHEMBL20142568 | 1.00 | DNM1 (0.46) | DNM1TSHRTHRBPLA2G1BPLA2G2A | |
| SCHEMBL11257179 | 1.00 | DNM1 (0.46) | DNM1TSHRTHRBPLA2G1BPLA2G2A | |
| SCHEMBL20142667 | 1.00 | DNM1 (0.46) | DNM1TSHRTHRBPLA2G1BPLA2G2A | |
| SCHEMBL14731786 | 1.00 | DNM1 (0.46) | DNM1TSHRTHRBPLA2G1BPLA2G2A | |
| SCHEMBL20142540 | 1.00 | DNM1 (0.46) | DNM1TSHRTHRBPLA2G1BPLA2G2A | |
| SCHEMBL9043631 | 1.00 | DNM1 (0.46) | DNM1TSHRTHRBPLA2G1BPLA2G2A | |
| SCHEMBL20142252 | 1.00 | DNM1 (0.46) | DNM1TSHRTHRBPLA2G1BPLA2G2A | |
| SCHEMBL20142537 | 1.00 | DNM1 (0.46) | DNM1TSHRTHRBPLA2G1BPLA2G2A | |
| SCHEMBL20142280 | 1.00 | DNM1 (0.46) | DNM1TSHRTHRBPLA2G1BPLA2G2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024123633-A1 | LIPID NANOPARTICLE COMPOSITIONS AND USES THEREOF | RECODE THERAPEUTICS, INC. (US) | 2024-06-13 | — | — | WO | disclosed |
| EP-3538575-B1 | HIGH CIS-1,4 BLOCK COPOLYMERS OF POLYBUTADIENE AND POLYISOPRENE | BRIDGESTONE CORP (JP) | 2024-03-13 | — | — | EP | disclosed |
| US-11884767-B2 | High cis-1,4 block copolymers of polybutadiene and polyisoprene | BRIDGESTONE CORPORATION (JP) | 2024-01-30 | — | — | US | disclosed |
| US-11696953-B2 | Poly(beta-amino esters) and uses thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2023-07-11 | — | — | US | disclosed |
| US-20220119573-A1 | HIGH CIS-1,4 BLOCK COPOLYMERS OF POLYBUTADIENE AND POLYISOPRENE | BRIDGESTONE CORPORATION (JP) | 2022-04-21 | — | — | US | disclosed |
| US-11230622-B2 | High cis-1,4 block copolymers of polybutadiene and polyisoprene | BRIDGESTONE CORPORATION (JP) | 2022-01-25 | — | — | US | disclosed |
| US-11041069-B2 | Gene delivery carrier | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2021-06-22 | — | — | US | disclosed |
| EP-3538575-A1 | HIGH CIS-1,4 BLOCK COPOLYMERS OF POLYBUTADIENE AND POLYISOPRENE | Bridgestone Corporation (JP) | 2019-09-18 | — | — | EP | disclosed |
| US-20190194444-A1 | GENE DELIVERY CARRIER | POLITECNICO DI MILANO (IT) | 2019-06-27 | — | — | US | disclosed |
| US-20190125874-A1 | POLY (BETA-AMINO ESTERS) AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2019-05-02 | — | — | US | disclosed |
| WO-2018089635-A1 | HIGH CIS-1,4 BLOCK COPOLYMERS OF POLYBUTADIENE AND POLYISOPRENE | BRIDGESTONE CORPORATION (JP) | 2018-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190194444-A1 | GENE DELIVERY CARRIER | PAICS, PBDC1, BCAT1 | DNM1 4619/4885TSHR 3794/4885THRB 2797/4885 |
| US-20190125874-A1 | POLY (BETA-AMINO ESTERS) AND USES THEREOF | BCAT1, BCAT2, SNRPE | DNM1 2479/4885TSHR 4387/4885THRB 1842/4885 |
| US-11041069-B2 | Gene delivery carrier | PAICS, PBDC1, BCAT1 | DNM1 4619/4885TSHR 3794/4885THRB 2797/4885 |
| US-11696953-B2 | Poly(beta-amino esters) and uses thereof | BCAT1, BCAT2, SNRPE | DNM1 2479/4885TSHR 4387/4885THRB 1842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.